hydroxychloroquine has been researched along with Rhabdomyolysis in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Rhabdomyolysis: Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kajani, R | 1 |
| Apramian, A | 1 |
| Vega, A | 1 |
| Ubhayakar, N | 1 |
| Xu, P | 1 |
| Liu, A | 1 |
| Valente-Acosta, B | 1 |
| Moreno-Sanchez, F | 1 |
| Fueyo-Rodriguez, O | 1 |
| Palomar-Lever, A | 1 |
2 other studies available for hydroxychloroquine and Rhabdomyolysis
| Article | Year |
|---|---|
Neuroleptic malignant syndrome in a COVID-19 patient.
Topics: Acute Kidney Injury; Antipsychotic Agents; Betacoronavirus; Bromocriptine; C-Reactive Protein; Coron | 2020 |
Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Azithromycin; Betaco | 2020 |